Trial · NCT02106494
Adverse events118
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 118
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Neutropenia | Blood and lymphatic system disorders | APF530 + Fosaprepitant + Dexamethasone | 26 | 456 | |
| other | Neutropenia | Blood and lymphatic system disorders | Ondansetron + Fosaprepitant + Dexamethasone | 30 | 459 | |
| other | Constipation | Gastrointestinal disorders | APF530 + Fosaprepitant + Dexamethasone | 99 | 456 | |
| other | Constipation | Gastrointestinal disorders | Ondansetron + Fosaprepitant + Dexamethasone | 70 | 459 | |
| other | Diarrhea | Gastrointestinal disorders | APF530 + Fosaprepitant + Dexamethasone | 39 | 456 | |
| other | Diarrhea | Gastrointestinal disorders | Ondansetron + Fosaprepitant + Dexamethasone | 35 | 459 | |
| other | Dyspepsia | Gastrointestinal disorders | APF530 + Fosaprepitant + Dexamethasone | 27 | 456 | |
| other | Dyspepsia | Gastrointestinal disorders | Ondansetron + Fosaprepitant + Dexamethasone | 32 | 459 | |
| other | Nausea | Gastrointestinal disorders | APF530 + Fosaprepitant + Dexamethasone | 75 | 456 | |
| other | Nausea | Gastrointestinal disorders | Ondansetron + Fosaprepitant + Dexamethasone | 71 | 459 | |
| other | Fatigue | General disorders | APF530 + Fosaprepitant + Dexamethasone | 95 | 456 | |
| other | Fatigue | General disorders | Ondansetron + Fosaprepitant + Dexamethasone | 109 | 459 | |
| other | Injection site bruising | General disorders | APF530 + Fosaprepitant + Dexamethasone | 191 | 456 | |
| other | Injection site bruising | General disorders | Ondansetron + Fosaprepitant + Dexamethasone | 154 | 459 | |
| other | Injection site erythema | General disorders | APF530 + Fosaprepitant + Dexamethasone | 77 | 456 | |
| other | Injection site erythema | General disorders | Ondansetron + Fosaprepitant + Dexamethasone | 127 | 459 | |
| other | Injection site haemorrhage | General disorders | APF530 + Fosaprepitant + Dexamethasone | 23 | 456 | |
| other | Injection site haemorrhage | General disorders | Ondansetron + Fosaprepitant + Dexamethasone | 36 | 459 | |
| other | Injection site nodule | General disorders | APF530 + Fosaprepitant + Dexamethasone | 82 | 456 | |
| other | Injection site nodule | General disorders | Ondansetron + Fosaprepitant + Dexamethasone | 45 | 459 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02106494/events